Kubota Pharmaceutical Holdings Co., Ltd. Logo

Kubota Pharmaceutical Holdings Co., Ltd.

A clinical-stage company developing drugs and devices for ophthalmic diseases.

4596 | T

Overview

Corporate Details

ISIN(s):
JP3266500002
LEI:
Country:
Japan
Address:
千代田区霞が関3丁目7番1号

Description

Kubota Pharmaceutical Holdings Co., Ltd., through its subsidiary Kubota Vision Inc., is a clinical-stage company dedicated to developing novel treatments for ophthalmic diseases. Its mission is to translate scientific innovation into a diverse portfolio of drugs and devices to preserve and restore vision for people worldwide. The company's development pipeline features emixustat hydrochloride, a therapeutic candidate for Stargardt disease. In the device segment, Kubota is commercializing Kubota Glass®, a wearable technology designed to manage myopia. The company focuses on creating solutions to address the root causes of blindness and vision impairment.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-19 07:30
訂正有価証券届出書(組込方式)
Japanese 247.7 KB
2025-11-17 01:00
有価証券届出書(組込方式)
Japanese 351.3 KB
2025-08-14 08:30
確認書
Japanese 8.4 KB
2025-08-14 08:30
半期報告書-第11期(2025/01/01-2025/12/31)
Japanese 230.5 KB
2025-07-31 08:37
訂正臨時報告書
Japanese 35.5 KB
2025-07-16 08:30
臨時報告書
Japanese 40.1 KB
2025-06-30 08:37
訂正臨時報告書
Japanese 28.6 KB
2025-06-20 08:30
臨時報告書
Japanese 27.5 KB
2025-04-21 08:30
臨時報告書
Japanese 23.8 KB
2025-03-28 08:10
確認書
Japanese 8.4 KB
2025-03-28 08:09
有価証券報告書-第10期(2024/01/01-2024/12/31)
Japanese 945.2 KB
2025-03-28 08:09
内部統制報告書-第10期(2024/01/01-2024/12/31)
Japanese 22.6 KB
2024-08-20 08:11
有価証券届出書(組込方式)
Japanese 231.3 KB
2024-08-14 08:03
確認書
Japanese 8.5 KB
2024-08-14 08:02
半期報告書-第10期(2024/01/01-2024/12/31)
Japanese 208.9 KB

Automate Your Workflow. Get a real-time feed of all Kubota Pharmaceutical Holdings Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kubota Pharmaceutical Holdings Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kubota Pharmaceutical Holdings Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Annexon, Inc. Logo
Clinical-stage biopharma developing complement medicines by inhibiting C1q.
United States of America
ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes cell therapies and orphan drugs using adult stem cells.
South Korea
065660
Antibiotice S.A. Logo
Pharmaceutical firm manufacturing generic medicines, anti-infectives, and APIs.
Romania
ATB
Apellis Pharmaceuticals, Inc. Logo
Biopharmaceutical company developing therapies by targeting the complement cascade.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Clinical-stage biopharma developing a bee venom drug and AI digital treasury solutions.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Clinical-stage biotech developing biologics for immunological and inflammatory diseases.
United States of America
APGE
Apollomics Inc. Logo
Clinical-stage biotech developing innovative oncology and combination therapies.
United States of America
APLM
Apontis Pharma AG Logo
Develops and markets fixed-dose combination drugs (Single Pills) for chronic diseases.
Germany
APPH
Applied Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel drugs for rare metabolic and CNS diseases.
United States of America
APLT
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologics and biosimilar antibody-based therapeutics.
South Korea
003060

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.